• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Oral Vaccination Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Syrian Hamster Challenge Model.口服疫苗可预防叙利亚仓鼠挑战模型中的严重急性呼吸综合征冠状病毒 2。
J Infect Dis. 2022 Jan 5;225(1):34-41. doi: 10.1093/infdis/jiab561.
2
Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.单次接种基于 chimpanzee 腺病毒的疫苗可诱导针对 SARS-CoV-2 感染的持续和保护性免疫。
Front Immunol. 2021 Jun 28;12:697074. doi: 10.3389/fimmu.2021.697074. eCollection 2021.
3
Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters.黏膜免疫接种 ChAd-SARS-CoV-2-S 可防止 SARS-CoV-2 向未接种疫苗的仓鼠连续传播。
Sci Adv. 2024 Aug 2;10(31):eadp1290. doi: 10.1126/sciadv.adp1290. Epub 2024 Jul 31.
4
One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.一剂 COVID-19 纳米颗粒疫苗 REVC-128 可在免疫后两周预防 SARS-CoV-2 挑战。
Emerg Microbes Infect. 2021 Dec;10(1):2016-2029. doi: 10.1080/22221751.2021.1994354.
5
Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.靶向刺突受体结合域的中和单克隆抗体赋予叙利亚仓鼠免受 SARS-CoV-2 感染的 Fc 受体非依赖性保护。
mBio. 2021 Oct 26;12(5):e0239521. doi: 10.1128/mBio.02395-21. Epub 2021 Sep 14.
6
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.基于水疱性口炎病毒-严重急性呼吸综合征冠状病毒 2 嵌合体的候选 COVID-19 疫苗的临床前免疫原性和疗效。
EBioMedicine. 2022 Aug;82:104203. doi: 10.1016/j.ebiom.2022.104203. Epub 2022 Jul 30.
7
Absence of Vaccine-enhanced Disease With Unexpected Positive Protection Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model.在叙利亚仓鼠模型中，在病毒攻击后 3 天内给予的灭活疫苗可提供对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的意外积极保护，而不会增强疾病。
Clin Infect Dis. 2021 Aug 2;73(3):e719-e734. doi: 10.1093/cid/ciab083.
8
A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.一剂重组 VSV-∆G 棘突蛋白疫苗可提供针对 SARS-CoV-2 挑战的保护。
Nat Commun. 2020 Dec 16;11(1):6402. doi: 10.1038/s41467-020-20228-7.
9
A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.一种基于人体细胞的 SARS-CoV-2 疫苗可引发强烈的中和抗体反应，并可保护小鼠免受 SARS-CoV-2 攻击。
Emerg Microbes Infect. 2021 Dec;10(1):1555-1573. doi: 10.1080/22221751.2021.1957400.
10
Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters.基于痘苗病毒的疫苗可使叙利亚仓鼠对新冠病毒产生保护性免疫。
PLoS One. 2021 Sep 9;16(9):e0257191. doi: 10.1371/journal.pone.0257191. eCollection 2021.

引用本文的文献

1
Novel vaccine strategies to induce respiratory mucosal immunity: advances and implications.诱导呼吸道黏膜免疫的新型疫苗策略：进展与影响
MedComm (2020). 2025 Jan 16;6(2):e70056. doi: 10.1002/mco2.70056. eCollection 2025 Feb.
2
Elimination of Human Papillomavirus 16-Positive Tumors by a Mucosal rAd5 Therapeutic Vaccination in a Pre-Clinical Murine Study.在一项临床前小鼠研究中，通过黏膜重组腺病毒5型治疗性疫苗消除人乳头瘤病毒16阳性肿瘤。
Vaccines (Basel). 2024 Aug 23;12(9):955. doi: 10.3390/vaccines12090955.
3
Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake.利用 NALT 和 BALT 的潜力，通过工程策略作为免疫调节的靶点，以增强黏膜摄取。
Front Immunol. 2024 Sep 2;15:1419527. doi: 10.3389/fimmu.2024.1419527. eCollection 2024.
4
Fasting before Intra-Gastric Dosing with Antigen Improves Intestinal Humoral Responses in Syrian Hamsters.抗原胃内给药前禁食可改善叙利亚仓鼠的肠道体液免疫反应。
Vaccines (Basel). 2024 May 24;12(6):572. doi: 10.3390/vaccines12060572.
5
Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19.口服一种新型 SARS-CoV-2 重组 RBD 抗原作为 COVID-19 护理的可能免疫刺激剂。
Microb Cell Fact. 2024 Feb 6;23(1):41. doi: 10.1186/s12934-024-02320-5.
6
Oral mucosa immunity: ultimate strategy to stop spreading of pandemic viruses.口腔黏膜免疫：阻止大流行病毒传播的终极策略。
Front Immunol. 2023 Oct 19;14:1220610. doi: 10.3389/fimmu.2023.1220610. eCollection 2023.
7
The impact of primary immunization route on the outcome of infection with SARS-CoV-2 in a hamster model of COVID-19.在新冠病毒（SARS-CoV-2）感染的仓鼠模型中，初次免疫途径对感染结果的影响。
Front Microbiol. 2023 May 24;14:1212179. doi: 10.3389/fmicb.2023.1212179. eCollection 2023.
8
Oral Administration of Universal Bacterium-Vectored Nucleocapsid-Expressing COVID-19 Vaccine is Efficacious in Hamsters.口服表达新冠病毒核衣壳的通用细菌载体疫苗对仓鼠有效。
Microbiol Spectr. 2023 Mar 14;11(2):e0503522. doi: 10.1128/spectrum.05035-22.
9
Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.黏膜免疫接种基于腺病毒 5 的疫苗可保护叙利亚仓鼠免受 SARS-CoV-2 的奥密克戎和德尔塔变异株的挑战。
Front Immunol. 2023 Feb 22;14:1086035. doi: 10.3389/fimmu.2023.1086035. eCollection 2023.
10
Mucosal delivery of nanovaccine strategy against COVID-19 and its variants.针对新冠病毒及其变体的纳米疫苗黏膜给药策略
Acta Pharm Sin B. 2022 Nov 21;13(7):2897-925. doi: 10.1016/j.apsb.2022.11.022.

本文引用的文献

1
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models.鼻内接种 ChAdOx1 nCoV-19/AZD1222 疫苗可减少临床前模型中 SARS-CoV-2 D614G 挑战后的病毒脱落。
Sci Transl Med. 2021 Aug 18;13(607). doi: 10.1126/scitranslmed.abh0755. Epub 2021 Jul 27.
2
A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.用黑猩猩腺病毒载体的SARS-CoV-2疫苗进行单次鼻内或肌肉内免疫可保护仓鼠免受肺炎侵害。
Cell Rep. 2021 Jul 20;36(3):109400. doi: 10.1016/j.celrep.2021.109400. Epub 2021 Jun 29.
3
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.ChAdOx1新型冠状病毒疫苗（AZD1222）候选疫苗显著减少了雪貂体内的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）脱落。
NPJ Vaccines. 2021 May 10;6(1):67. doi: 10.1038/s41541-021-00315-6.
4
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
5
IgA dominates the early neutralizing antibody response to SARS-CoV-2.IgA 在针对 SARS-CoV-2 的早期中和抗体反应中占主导地位。
Sci Transl Med. 2021 Jan 20;13(577). doi: 10.1126/scitranslmed.abd2223. Epub 2020 Dec 7.
6
Enhanced SARS-CoV-2 neutralization by dimeric IgA.二聚体 IgA 增强对 SARS-CoV-2 的中和作用。
Sci Transl Med. 2021 Jan 20;13(577). doi: 10.1126/scitranslmed.abf1555. Epub 2020 Dec 7.
7
Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk.在人乳中检测到针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的强大且特异性分泌型免疫球蛋白A
iScience. 2020 Nov 20;23(11):101735. doi: 10.1016/j.isci.2020.101735. Epub 2020 Oct 26.
8
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.COVID-19 患者血清和唾液中针对 SARS-CoV-2 刺突抗原的抗体反应持续存在。
Sci Immunol. 2020 Oct 8;5(52). doi: 10.1126/sciimmunol.abe5511.
9
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.Ad26 疫苗可预防仓鼠的严重 SARS-CoV-2 临床疾病。
Nat Med. 2020 Nov;26(11):1694-1700. doi: 10.1038/s41591-020-1070-6. Epub 2020 Sep 3.
10
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development.叙利亚仓鼠作为 SARS-CoV-2 感染及对策研发的小动物模型。
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595. doi: 10.1073/pnas.2009799117. Epub 2020 Jun 22.

口服疫苗可预防叙利亚仓鼠挑战模型中的严重急性呼吸综合征冠状病毒 2。

Oral Vaccination Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Syrian Hamster Challenge Model.

机构信息

Vaxart, South San Francisco, California, USA.

Lovelace Biomedical Research Institute, Albuquerque, New Mexico, USA.

出版信息

J Infect Dis. 2022 Jan 5;225(1):34-41. doi: 10.1093/infdis/jiab561.

DOI:10.1093/infdis/jiab561
PMID:34758086
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8689930/
Abstract

BACKGROUND

Vaccines that are shelf stable and easy to administer are crucial to improve vaccine access and reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission around the world.

METHODS

In this study, we demonstrate that an oral, adenovirus-based vaccine candidate protects against SARS-CoV-2 in a Syrian hamster challenge model.

RESULTS

Hamsters administered 2 doses of VXA-CoV2-1 showed a reduction in weight loss and lung pathology and had completely eliminated infectious virus 5 days postchallenge. Oral immunization induced antispike immunoglobulin G, and neutralizing antibodies were induced upon oral immunization with the sera, demonstrating neutralizing activity.

CONCLUSIONS

Overall, these data demonstrate the ability of oral vaccine candidate VXA-CoV2-1 to provide protection against SARS-CoV-2 disease.

摘要

背景

易于储存和管理的疫苗对于改善疫苗的可及性和减少全球范围内严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的传播至关重要。

方法

在这项研究中，我们证明了一种基于腺病毒的口服疫苗候选物可在叙利亚仓鼠挑战模型中预防 SARS-CoV-2。

结果

接受 2 剂 VXA-CoV2-1 治疗的仓鼠体重减轻和肺部病理学减少，并且在挑战后 5 天完全消除了传染性病毒。口服免疫可诱导抗刺突免疫球蛋白 G，并且用血清进行口服免疫可诱导中和抗体，显示出中和活性。

结论

总体而言，这些数据表明口服疫苗候选物 VXA-CoV2-1 有能力预防 SARS-CoV-2 疾病。